Zuranolone is a Small Molecule owned by Sage Therapeutics, and is involved in 21 clinical trials, of which 14 were completed, 6 are ongoing, and 1 is planned.
Zuranolone (SAGE-217) acts as GABAA receptor allosteric modulator. GABA helps in maintaining appropriate electrical activity. The drug candidate is coupled to gamma-aminobutyric acid-A (GABAA) receptors and enhances the effects of GABA by increasing GABA affinity for the GABAA receptor. Binding of GABA to the site opens the chloride channel, resulting in a hyper polarized cell membrane that prevents further excitation of the cell. The ability to up-regulate and down-regulate GABA-A with high selectivity helps in the treatment of the disease with high specificity.
The revenue for Zuranolone is expected to reach a total of $1.7bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Zuranolone NPV Report.
Zuranolone (SAGE-217, SAGE-NCE) is under development for the treatment of postpartum depression, bipolar disorder, major depressive disorder and generalized anxiety disorder. It is administered by the oral route. It is a new chemical entity (NCE) that targets GABAA receptor. SAGE-NCE is developed based on positive and negative allosteric modulator (PANAM) chemistry platform. It was also under development as an intravenous therapy for refractory status epilepticus (RSE) and as an oral therapy for orphan genetic epilepsy disorders, such as Dravet syndrome, Rett syndrome and Fragile X syndromes. The drug candidate was also under development for essential tremors, dyskinesias, insomnia and Parkinson’s disease.
Shionogi & Overview
Shionogi & (Shionogi) focuses on the research, development, manufacturing, and marketing of pharmaceutical products, diagnostic reagents, and medical devices. It develops innovative products and services in collaboration with its partners. The company offers prescription drugs, over-the-counter (OTC) drugs, and diagnostic products for the therapeutic areas including metabolic disorders, infectious diseases, pain/central nervous system (CNS), and cancer. It offers contract development and manufacturing facilities including all stages from drug development to commercial manufacturing. The company operates a network of subsidiaries, branches, sales offices manufacturing plants, and research laboratories across Japan, China, Taiwan; North America and Europe. Shionogi is headquartered in Osaka, Japan.
The company reported revenues of (Yen) JPY335,138 million for the fiscal year ended March 2022 (FY2022), an increase of 12.8% over FY2021. In FY2022, the company’s operating margin was 32.9%, compared to an operating margin of 39.5% in FY2021. In FY2022, the company recorded a net margin of 34.1%, compared to a net margin of 37.6% in FY2021. The company reported revenues of JPY78,939 million for the second quarter ended September 2022, an increase of 9.9% over the previous quarter.
Quick View – Zuranolone
|Highest Development Stage|